DSpace Collection:https://hdl.handle.net/10171/194632024-03-28T08:45:16Z2024-03-28T08:45:16ZGLP-1 limits adipocyte inflammation and its low circulating pre-operative concentrations predict worse type 2 diabetes remission after bariatric surgery in obese patientshttps://hdl.handle.net/10171/622182021-10-22T01:05:48Z2019-01-01T00:00:00ZTitle: GLP-1 limits adipocyte inflammation and its low circulating pre-operative concentrations predict worse type 2 diabetes remission after bariatric surgery in obese patients
Abstract: Objective: Glucagon-like peptide (GLP)-1 has been proposed as a key candidate in glucose
improvements after bariatric surgery. Our aim was to explore the role of GLP-1 in surgically-induced
type 2 diabetes (T2D) improvement and its capacity to regulate human adipocyte inflammation.
Methods: Basal circulating concentrations of GLP-1 as well as during an oral glucose tolerance test
(OGTT) were measured in lean and obese volunteers with and without T2D (n = 93). In addition,
GLP-1 levels were determined before and after weight loss achieved by Roux-en-Y gastric bypass
(RYGB) (n = 77). The impact of GLP-1 on inflammation signalling pathways was also evaluated.
Results: We show that the reduced (p < 0.05) circulating levels of GLP-1 in obese T2D patients
increased (p < 0.05) after RYGB. The area under the curve was significantly lower in obese patients
with (p < 0.01) and without (p < 0.05) T2D compared to lean volunteers while obese patients with
T2D exhibited decreased GLP-1 levels at baseline (p < 0.05) and 120 min (p < 0.01) after the OGTT.
Importantly, higher (p < 0.05) pre-operative GLP-1 concentrations were found in patients with
T2D remission after RYGB. We also revealed that exendin-4, a GLP-1 agonist, downregulated the
expression of inflammation-related genes (IL1B, IL6, IL8, TNF) and, conversely, upregulated the
mRNA levels of ADIPOQ in human visceral adipocytes. Furthermore, exendin-4 blocked (p < 0.05)
LPS-induced inflammation in human adipocytes via downregulating the expression and secretion of
key inflammatory markers. Conclusions: Our data indicate that GLP-1 may contribute to glycemic
control and exert a role in T2D remission after RYGB. GLP-1 is also involved in limiting inflammation
in human visceral adipocytes.2019-01-01T00:00:00Z